Kaplan-Meier analyses of patients with or without a BCR-ABL mutation who received dasatinib treatment at any dose or 100 mg once daily (QD) after resistance or suboptimal response to imatinib. (A) Duration of complete cytogenetic response (CCyR). (B) Progression-free survival (PFS). (C) Overall survival (OS).